Advancing with Purpose, Growing through Innovation
A New Year Message from the Chairman & CEO of BioPerfectus
As the year draws to a close and the Lunar New Year approaches, we stand once again at a moment of renewal. The idea of a “new year” carries a quiet but powerful meaning—no matter what the past has held, it invites us to reset our focus, regain momentum, and move forward with clarity and confidence.
The year 2025 was a defining period for BioPerfectus—a year of steady consolidation and strategic realignment. Against the backdrop of overlapping economic cycles, healthcare policy reforms, and structural adjustments in the post-pandemic era, recovery was neither immediate nor effortless. Yet amid global uncertainty across technology, regulation, and market dynamics, we maintained stable operations and demonstrated clear signs of resilience and recovery.
I would like to express my sincere respect and gratitude to our team, whose determination and commitment never wavered in a demanding business environment. I am equally thankful to our customers and partners, whose long-term trust and support have remained constant throughout this journey.
Since taking our first steps toward international expansion, BioPerfectus has pursued a strategy of “going global while staying local.” Built on deep expertise in infectious disease diagnostics, we have played an active role in responding to major global public health challenges. Our dengue virus detection products have been listed under the WHO Emergency Use Listing Procedure (ERPD), and our mpox molecular diagnostic assays have been approved for inclusion in the WHO Emergency Use Listing (EUL).
These high-standard international recognitions continue to translate into durable competitive advantages, strengthening BioPerfectus’ participation in global public health systems and enhancing our international brand presence. With diagnostic solutions that are precise, rapid, cost-effective, and highly accessible, we are confident in becoming an increasingly important contributor to healthcare systems across more countries.
Looking ahead, 2026 is expected to mark a turning point in BioPerfectus’ return to sustained growth. With accelerating global expansion, breakthroughs in high-barrier product categories, and the coordinated development of a diversified business matrix, new growth drivers are rapidly converging. We are entering a new phase powered by innovation and operational efficiency.
Standing at this new starting point, challenges undoubtedly remain. Yet with a steadfast commitment to our users, respect for the market, and continuous capability building, we are confident in navigating uncertainty and welcoming the next season of growth.
In the dynamic global IVD landscape—where opportunity and competition coexist—we will continue to move forward with determination on our mission: to protect life and health through precision diagnostics. Together, we are prepared to navigate the waves ahead and move toward a future of shared success.
Dr. Guoqiang Wang
Chairman & Chief Executive Officer
BioPerfectus
